Holding company Innoviva is acquiring late-stage antibiotic biotech Entasis Therapeutics, a 2015 AstraZeneca spinout that just posted phase 3 results worthy of an FDA filing last year. Innoviva ...
Innoviva to acquire all outstanding shares of Entasis it does not already own for $2.20 per share in cash Price per share in cash represents a 50% premium to Entasis’ closing price of $1.47 per share ...
Entasis Therapeutics steered its lead antibiotic candidate through late-stage clinical development with help from Innoviva, which has steadily invested in the company over the past two years and now ...
Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care 87 million new gonorrhea infections ...
WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ...
WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced initiation ...
Entasis Scores! The FDA's anti-infectives advisory board unanimously recommended approval of Entasis sulbactam-durlobactam for the treatment of hospital and ventilator-acquired pneumonia, caused by ...
WASHINGTON — Entasis Therapeutics announced at the World Anti-Microbial Resistance Congress that it has enrolled the first patient in a global phase 3 trial of oral zoliflodacin for the treatment of ...
The U.S. dithers, Europe ponders and the extinction of life-saving antibiotics continues apace. Here we go again. Entasis Therapeutics has been struggling in the public marketplace. There is certainly ...
Entasis Therapeutics has progress to report in its quest to bring patients an antibiotic that can take on drug-resistant bacteria. The company’s lead antibiotic candidate has met the main goal of a ...
BURLINGAME, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback